發(fā)布時(shí)間：2019-05-07 05:49

【摘要】：目的:探究表皮生長(zhǎng)因子受體(epidermal growth factor receptor,EGFR)對(duì)于老年食管癌患者進(jìn)行同步放化療的敏感性進(jìn)行預(yù)測(cè),具有十分重要的臨床意義與價(jià)值。方法:選取我院2014年7月-2015年7月期間收治的老年食管鱗癌患者共60例,其中男56例、女4例,年齡65-77歲。病變部位為胸段,病變長(zhǎng)度2.5-8cm不等,TNM分期II-III期。其中:胸上段20例,占34%(20/60),胸中段23例,占38%(23/60),胸下段17例,占28%(17/60)。II期患者30例,占50%(30/60),III期患者30例,占50%(30/60)。獲取患者腫瘤組織的病理標(biāo)本,經(jīng)免疫組織化學(xué)染色確定EGFR表達(dá)性質(zhì)。食管癌放療方案:6MV-X體外照射,靶區(qū)劑量45-60Gy,單次分割劑量2Gy/次,5次/W。均于放療開(kāi)始后行同步化療。給予患者紫杉醇聯(lián)合順鉑化療方案(紫杉醇135mg/m2 d1,順鉑20mg/m2 d1-5)。同步化療每3周為一個(gè)療程,共行2個(gè)療程。療程過(guò)后,通過(guò)食管鋇及造影對(duì)患者進(jìn)行全面的復(fù)查,并且將結(jié)果分為:完全緩解、部份緩解與無(wú)緩解三類。最后比較兩組患者EGFR表達(dá)與同步放化療緩解率的關(guān)系。結(jié)果:根據(jù)免疫組織化學(xué)評(píng)分法,將60例標(biāo)本分為EGFR表達(dá)陽(yáng)性41例和陰性19例,進(jìn)行了EGFR表達(dá)且結(jié)果呈現(xiàn)陽(yáng)性的標(biāo)本當(dāng)中,大多數(shù)的細(xì)胞質(zhì)以及細(xì)胞膜都被染色,且均呈現(xiàn)出棕褐色。而EGFR表達(dá)且結(jié)果呈現(xiàn)陰性的一系列標(biāo)本中,絕大多數(shù)的細(xì)胞沒(méi)有發(fā)生著色現(xiàn)象。在EGFR的陽(yáng)性組患者當(dāng)中,28例患者的癥狀得到了完全意義上的緩解,19例患者部份癥狀得以緩解,4例患者癥狀沒(méi)有絲毫的緩解;在EGFR的陰性組患者當(dāng)中,3例患者的癥狀得到了完全意義上的緩解,10例患者部份癥狀得以緩解,6例患者癥狀沒(méi)有絲毫的緩解;將兩組結(jié)果進(jìn)行綜合的對(duì)比分析,EGFR陽(yáng)性組癥狀緩解率(68.29%)明顯高于陰性組(15.79%),且差異存在統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:老年食管癌患者EGFR陽(yáng)性組同步放化療后癥狀緩解率明顯高于陰性組。老年食管癌EGFR表達(dá)水平的高低可能在預(yù)測(cè)其同步放化療敏感性中起到重要作用。
[Abstract]:Aim: to explore the sensitivity of epidermal growth factor receptor (epidermal growth factor receptor,EGFR) to concurrent radiotherapy and chemotherapy in elderly patients with esophageal carcinoma, which is of great clinical significance and value. Methods: from July 2014 to July 2015, 60 elderly patients with esophageal squamous cell carcinoma were selected, including 56 males and 4 females, aged 65 to 77 years. The lesion was located in the thoracic segment, the length of the lesion was 2.5-8cm, and the TNM stage was II-III stage. Among them, 20 cases were upper thoracic segment (34%), 23 cases were middle thoracic segment (38%), 17 cases were lower thoracic segment (28%), 30 cases were in stage II (50%), 30 cases were in stage III (30 cases), 30 cases were in stage III (30 cases), 23 cases were in middle segment (38%, 23%), 17 cases were in lower segment of chest (28%). 50% (30 / 60). The pathological specimens of tumor tissue were obtained and the expression of EGFR was determined by immunohistochemical staining. Radiotherapy regimen for esophageal cancer: 6MV-X irradiation in vitro, target dose of 45? 60 Gy, single dose of 2Gy/, 5 times / W. All patients were treated with concurrent chemotherapy after the beginning of radiotherapy. Patients were given paclitaxel plus cisplatin chemotherapy regimen (paclitaxel 135mg/m2 D1, cisplatin 20mg/m2 D1, 5). Synchronous chemotherapy was a course of treatment every 3 weeks, and 2 courses were performed. After the course of treatment, the patients were reviewed by esophageal barium and angiography, and the results were divided into three groups: complete remission, partial remission and non-remission. Finally, the relationship between the expression of EGFR and the remission rate of concurrent radiotherapy and chemotherapy was compared between the two groups. Results: according to the immunohistochemical method, 60 specimens were divided into 41 positive and 19 negative for EGFR expression. Most of the samples with positive EGFR expression were stained with cytoplasm and cell membrane. And all of them are brownish brown. In a series of samples with negative expression of EGFR, no staining was found in most of the cells. In the EGFR positive group, the symptoms of 28 patients were completely relieved, 19 patients were partially relieved, and 4 patients had no remission. In the negative group of EGFR, the symptoms of 3 patients were completely relieved, 10 patients were partially relieved, and 6 patients were not relieved. The results showed that the symptom remission rate of EGFR positive group (68.29%) was significantly higher than that of negative group (15.79%), and the difference was statistically significant (P0.05). Conclusion: the symptom remission rate of EGFR positive group was significantly higher than that of negative group. The expression level of EGFR in elderly esophageal carcinoma may play an important role in predicting the sensitivity of concurrent radiotherapy and chemotherapy.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張朝東,馬冬春,嚴(yán)中亞,高理錦;老年食管癌的外科治療[J];華北煤炭醫(yī)學(xué)院學(xué)報(bào);2000年04期

2 楊傳平,丁航宇,王朝敏;70歲以上老年食管癌36例外科治療[J];實(shí)用老年醫(yī)學(xué);2003年04期

3 牟旭日,于紅玲;老年食管癌患者的外科治療[J];臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志;2004年02期

4 馬麗,趙海燕;老年食管癌術(shù)后護(hù)理[J];實(shí)用醫(yī)技雜志;2004年07期

5 李方明,聶青,袁卓庭;老年食管癌患者放療后長(zhǎng)期生存2例報(bào)告[J];中華放射醫(yī)學(xué)與防護(hù)雜志;2004年06期

6 馮士云;張哲峰;姜丁源;崔有斌;;老年食管癌患者69例手術(shù)治療及臨床特點(diǎn)[J];中國(guó)老年學(xué)雜志;2013年05期

7 張柯;;老年食管癌患者的手術(shù)治療分析[J];中國(guó)實(shí)用醫(yī)藥;2013年08期

8 陳蕾;;老年食管癌患者術(shù)后護(hù)理體會(huì)[J];內(nèi)蒙古中醫(yī)藥;2013年29期

9 梁炎;52例老年食管癌圍手術(shù)期的處理要點(diǎn)與體會(huì)[J];廣東醫(yī)學(xué)院學(xué)報(bào);2001年05期

10 王明榮,楊康,楊軍民,王海東;老年食管癌的外科治療[J];重慶醫(yī)學(xué);2002年05期

相關(guān)會(huì)議論文 前10條

1 陳景禮;;同期放、化療聯(lián)合區(qū)域性熱療治療老年食管癌的臨床研究[A];第三屆中國(guó)腫瘤內(nèi)科大會(huì)教育集暨論文集[C];2009年

2 任躍君;;182例老年食管癌患者放療的護(hù)理體會(huì)[A];中華護(hù)理學(xué)會(huì)全國(guó)腫瘤護(hù)理學(xué)術(shù)交流暨專題講座會(huì)議論文匯編[C];2009年

3 王于;郭祥云;涂遠(yuǎn)榮;蘇祖棟;;老年食管癌的外科治療[A];全國(guó)食管癌診斷與治療新技術(shù)研討會(huì)論文集[C];2006年

4 劉建偉;曲波;;老年食管癌的圍術(shù)期處理[A];中華醫(yī)學(xué)會(huì)第六次全國(guó)胸心血管外科學(xué)術(shù)會(huì)議論文集（胸外科分冊(cè)）[C];2006年

5 祝鑫海;具晟;陳國(guó)平;舒躍;魯高鋒;袁豐;;老年食管癌患者圍術(shù)期營(yíng)養(yǎng)治療的研究[A];第三屆江浙滬三地老年醫(yī)學(xué)高峰論壇暨2012年浙江省老年醫(yī)學(xué)學(xué)術(shù)年會(huì)論文集[C];2012年

6 張新良;王曉萍;張道富;傅辰春;丁巍;劉麗;周衛(wèi)紅;;41例老年食管癌的臨床特點(diǎn)和放療療效觀察[A];中華醫(yī)學(xué)會(huì)放射腫瘤治療學(xué)分會(huì)六屆二次暨中國(guó)抗癌協(xié)會(huì)腫瘤放療專業(yè)委員會(huì)二屆二次學(xué)術(shù)會(huì)議論文集[C];2009年

7 王哲;;老年食管癌術(shù)后的護(hù)理[A];全國(guó)外科、神經(jīng)內(nèi)外科護(hù)理學(xué)術(shù)交流暨專題講座會(huì)議論文匯編[C];2006年

8 劉建偉;曲波;;老年食管癌的外科治療[A];第二十二屆航天醫(yī)學(xué)年會(huì)暨第五屆航天護(hù)理年會(huì)論文匯編（上冊(cè)）[C];2006年

9 趙玉霞;金劍;;老年食管癌患者放療中心營(yíng)養(yǎng)及心理狀態(tài)問(wèn)題探討[A];中國(guó)營(yíng)養(yǎng)學(xué)會(huì)第八次全國(guó)營(yíng)養(yǎng)學(xué)術(shù)會(huì)議論文摘要匯編[C];2000年

10 李桂芳;孫海;冉兵;陳潔;周小鳳;;光動(dòng)力聯(lián)合化療治療老年食管癌患者的臨床研究[A];第三屆中國(guó)腫瘤內(nèi)科大會(huì)教育集暨論文集[C];2009年

相關(guān)博士學(xué)位論文 前1條

1 汪紅艷;老年食管癌放射治療療效及預(yù)后相關(guān)研究[D];安徽醫(yī)科大學(xué);2016年

相關(guān)碩士學(xué)位論文 前5條

1 姚忠彬;EGFR在預(yù)測(cè)老年食管癌患者同步放化療敏感性中的作用及其臨床意義研究[D];吉林大學(xué);2017年

2 祝鑫海;老年食管癌圍手術(shù)期營(yíng)養(yǎng)治療的研究[D];浙江大學(xué);2011年

3 湯曉偉;改良老年疾病累計(jì)評(píng)分表在老年食管癌患者中的應(yīng)用[D];安徽醫(yī)科大學(xué);2010年

4 張連杰;三種營(yíng)養(yǎng)方式對(duì)老年食管癌患者術(shù)后早期康復(fù)的效果觀察[D];吉林大學(xué);2012年

5 馬駿;左胸微創(chuàng)切口在老年食管癌患者手術(shù)治療中的臨床觀察[D];山西醫(yī)科大學(xué);2012年

，

本文編號(hào)：2470818